Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'The Merck Index' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Drugs: Synonyms and Properties Version 2.1 |
October 2004 | £175 | 50 % |
|
Merck KGaA Deals Partneringdesk briefing |
July 2005 | £215 | 44 % |
|
Merck & Co Inc Deals Partneringdesk briefing |
July 2005 | £215 | 42 % |
|
Merck Druggernaut; The The Inside Story of a Pharmaceutical Giant |
March 2005 | £11.99 | 35 % |
|
Novel Mitotic Kinase Inhibitors Competitor Analysis |
May 2009 | £305 | 33.95 % |
|
Merck & Co and Schering-Plough - a marriage of convenience? |
August 2009 | £295 | 33.25 % |
|
Attention-Deficit Hyperactivity Disorder (ADHD) Competitor Analysis |
March 2009 | £175 | 32.9 % |
|
MarketWatch: Health Round-up |
October 2008 | £215 | 27.65 % |
|
Ras-Raf-MEK-ERK Inhibitors Competitor Analysis |
May 2009 | £305 | 26.6 % |
|
CXCR and CXCL Agonists and Antagonists Competitor Analysis |
November 2009 | £260 | 26.25 % |
|
Anti-Infective Peptides Competitor Analysis |
January 2009 | £260 | 25.9 % |
|
Pharma Corporate Venture Capital (CVC): key players, new conditions and big opportunities |
September 2009 | £295 | 25.9 % |
|
FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART) Competitor Analysis |
November 2009 | £175 | 24.85 % |
|
Partneringdesk deals and alliances in infectious diseases |
April 2006 | £1250 | 24.5 % |
|
MarketWatch: Health Roundup |
November 2008 | £215 | 24.5 % |
|
Partneringdesk deals and alliances in metabolic diseases |
April 2006 | £1250 | 24.5 % |
|
Nycomed Pipeline Products Performance Potential |
October 2007 | £595 | 24.15 % |
|
Allergan: Pipeline , Products , Performance , Potential |
February 2008 | £595 | 23.8 % |
|
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Competitor Analysis |
November 2008 | £260 | 23.8 % |
|
Dainippon Sumitomo: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 23.8 % |
|
Partneringdesk deals and alliances in autoimmune & inflammatory diseases |
April 2006 | £1250 | 23.5 % |
|
UCB Prospects to 2010 |
November 2008 | £595 | 23.1 % |
|
PI3K-Akt-mTOR Pathway Inhibitors Competitor Analysis |
July 2009 | £435 | 23.1 % |
|
Forest Laboratories Pipeline Products Performance Potential |
October 2007 | £595 | 23.1 % |
|
Bristol-Myers Squibb Pipeline, Products, Performance, Potential |
February 2008 | £595 | 22.75 % |
|
Johnson & Johnson: Pharma Growth Strategy How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues? |
July 2009 | £245 | 22.4 % |
|
Partneringreview 2006 - Company Deal Index Volume 1 |
February 2006 | £1395 | 21.5 % |
|
Competitor Analysis: Tissue Growth Factors |
December 2009 | £700 | 20.65 % |
|
AstraZeneca: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 20.65 % |
|
Gilead Sciences Performance, Products, Pipeline and Potential |
February 2008 | £595 | 20.3 % |
|
Dainippon Sumitomo Pipeline Products Performance Potential |
December 2008 | £595 | 19.95 % |
|
Partneringreview 2006 |
February 2006 | £2195 | 19.5 % |
|
Innovations in The Management of Diabetes Next generation treatments and market dynamics |
June 2008 | £1995 | 19.25 % |
|
Partneringreview 2006 – Financings Volume 3 |
February 2006 | £1395 | 19 % |
|
Partneringreview 2006 – Deal Type Volume 5 |
February 2006 | £1395 | 18.5 % |
|
Partneringreview 2006 – Stage of Development Volume 4 |
February 2006 | £1395 | 18.5 % |
|
Partneringreview 2006 – Therapy Area Volume 2 |
February 2006 | £1395 | 18.5 % |
|
Partneringreview 2006 – Industry Sector Volume 6 |
February 2006 | £1395 | 18.5 % |
|
The Global HIV/Aids Market Outlook To 2012 |
July 2007 | £1495 | 17.5 % |
|
Roche: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 17.15 % |
|
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011 |
June 2006 | £1495 | 16.8 % |
|
Future Growth Opportunities in Generics The impact of consolidation on market and competitive dynamics |
November 2006 | £1495 | 16.45 % |
|
Emerging Diabetes Drugs Competitor Analysis |
November 2008 | £525 | 16.1 % |
|
Johnson & Johnson Deals Partneringdesk briefing |
July 2005 | £215 | 16 % |
|
next-Generation Immunoassays A Market and Technical Analysis of Research Applications 2007 |
December 2007 | £2300 | 15.75 % |
|
Pfizer Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 15.4 % |
|
Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders |
December 2008 | £2385 | 15.05 % |
|
Key Trends in Offshoring Pharmaceutical R&D Company strategies, emerging markets and impact on ROI |
March 2009 | £2025 | 15.05 % |
|
The Cardiovascular Market Outlook to 2013 Competitive Landscape, Global Market Analysis and Pipeline Analysis |
January 2009 | £2025 | 15.05 % |
|
Diabetes Market Outlook to 2011; The |
May 2006 | £1495 | 14.7 % |
|
Inflammatory Directions Strategies for Six Diseases with Unmet Needs |
April 2008 | £715 | 14.7 % |
|
Otsuka Prospects to 2010 |
August 2007 | £249 | 14.35 % |
|
Effective Deal Making in Drug Delivery |
April 2009 | £3594 | 14.35 % |
|
Effective Licensing & Commercialisation of Drug Delivery Systems 2006 |
July 2006 | £2500 | 14 % |
|
Innovations In Epigenetics Advances in Technologies, Diagnostics & Therapeutics |
November 2009 | £3835 | 14 % |
|
The Global Anti-Infectives Market Outlook to 2011 |
June 2007 | £1495 | 13.65 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 13.65 % |
|
The Cardiovascular Disorders Market Outlook to 2012 |
February 2008 | £1995 | 13.65 % |
|
The Asian Cardiovascular Market Outlook to 2014 Regional and therapeutic analysis, pipeline impact and growth opportunities |
March 2009 | £2025 | 13.3 % |
|
Spain Pharmaceuticals & Healthcare |
July 2006 | £395 | 13 % |
|
Immunotherapies and Vaccines for Cancer and Infectious Diseases |
October 2008 | £2385 | 12.95 % |
|
Protease Inhibitors Innovation Drives Drug Pipeline |
February 2009 | £2385 | 12.6 % |
|
Cancer Cell Therapy Markets |
March 2008 | £2165 | 12.25 % |
|
Nuclear Cardiology Markets |
December 2007 | £1270 | 12.25 % |
|
The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape |
May 2007 | £1590 | 11.9 % |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 | 11.55 % |
|
United States Pharmaceuticals and Healthcare Report Q3 2006 |
July 2006 | £395 | 11.5 % |
|
Blood-Brain Barrier Bridging Options for Drug Discovery and Development |
May 2008 | £715 | 10.85 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £715 | 10.85 % |
|
Siemens Healthcare Medical Device Company Intelligence Report |
August 2009 | £295 | 9.1 % |
|
Drug Treatments for Leading Endocrine and Metabolic Diseases |
February 2007 | £3085 | 8.75 % |
|
RNA Interference Markets |
December 2008 | £2165 | 8.75 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £6000 | 8.75 % |
|
Top 10 Generic Pharmaceutical Companies, The Positioning, Performance and SWOT Analyses |
July 2008 | £1995 | 8.4 % |
|
Global Image Dermatology Drug Market, 2005-2012, The High-Growth Opportunities in Aesthetic Medicine |
November 2005 | £795 | 8.4 % |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1045 | 8.4 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2140 | 8.05 % |
|
Biosimilars: a viable market? |
September 2008 | £1295 | 8.05 % |
|
The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses |
March 2009 | £2025 | 7.7 % |
|
The Cancer Market Outlook To 2014 Competitive landscape, market size, pipeline analysis and growth opportunities |
January 2010 | £3835 | 7.7 % |
|
Innovative Clinical Trial Design and Management Trends, Success Stories and Impact upon R&D Budgets |
May 2008 | £1995 | 7.7 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2009 / 2010 |
June 2009 | £270 | 7 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £270 | 6.65 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2165 | 6.65 % |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 | 6.3 % |
|
Anti-Obesity Treatments Analysis & Forecasts 2009-2024 |
February 2009 | £1499 | 6.3 % |
|
Commercial Insight: Antidiabetics in Australia Reimbursement status shapes novel classes |
October 2010 | £5700 | 5.95 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £795 | 5.6 % |
|
Anti-Obesity Treatments 2007-2012 - A blockbuster target market |
July 2007 | £1799 | 5.25 % |
